ElevateBio Raises $525m To Expand Cell And Gene Therapy Expertise
With $845m raised to date, ElevateBio will keep building its cell and gene therapy manufacturing capabilities and continue creating new companies and partnerships, but with a global focus.
You may also be interested in...
Moderna and Life Edit will team up to develop transformative or curative therapies for challenging genetic diseases. Erytech and Pherecydes unveil plan to merge and extend runway into 2024.
Gaining the special regulatory status in a prophylactic setting for posoleucel is the most significant yet for the T cell therapy developer.
Private Company Edition: The latest $100m-plus VC financings include $112.5m for PepGen, Deep Genomics’ $180m series C round and a $166m series D for Rakuten Medical. Also, Lumira Ventures raised a $220m fourth fund and will manage a separate $35m fund backed by Angelini Pharma.